

**DANIEL M. MILLER**  
**Partner**  
**(604) 630-5199**  
**FAX (604) 687-8504**  
**[miller.dan@dorsey.com](mailto:miller.dan@dorsey.com)**

October 30, 2024

Division of Corporation Finance  
Office of Life Sciences  
U.S. Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549  
Attention: Jimmy McNamara and Joe McCann

**Re: Aptose Biosciences Inc.**  
**Registration Statement on Form S-1**  
**Filed August 2, 2024**  
**File No. 333-281201**

Dear Sirs and Mesdames:

On behalf of our client, Aptose Biosciences Inc. (the “Company”), and pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder, we transmit for your review the Company’s response to the Staff’s letter of comment, dated August 2, 2024 (the “Comment Letter”), in respect of the above noted filing. The Company’s response below is keyed to the heading and comment number contained in the Comment Letter.

**Registration Statement on Form S-1**

**Cover Page**

- 1. Please revise your cover page to disclose the date your best efforts offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K for guidance.**

The requested disclosure has been provided on the cover page of the prospectus.

\* \* \*

U.S. Securities and Exchange Commission  
October 30, 2024  
Page 2

Should you have further comments or require further information, or if any questions should arise in connection with this submission, please call the undersigned at (604) 630-5199. You also may email me at [dmiller.dan@dorsey.com](mailto:dmiller.dan@dorsey.com) or fax me at (604) 687-8504.

Yours truly,

/s/ Daniel M. Miller

cc: William G. Rice  
Fletcher Payne  
Aptose Biosciences Inc.